RIPE-KG · Version 1.1.0 · Resource

ripekg:publication-details/RIPEAE59AF25CB9D16527

https://w3id.org/ripe/ripe-kg/publication-details/RIPEAE59AF25CB9D16527
SubjectPredicateObject
ripekg:evaluation/RIPEAE59AF25CB9D16527 prov:used ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial prism:eIssn 1399-3038
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial prism:endingPage 840
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial prism:issn 0905-6157
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial prism:publicationDate 2018-09-28
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial prism:publicationName Pediatric Allergy and Immunology
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial prism:startingPage 834
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial dcterms:publisher ripekg:publisher/RIPEP932ECA8E36309A4DWiley
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial dcterms:title EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial rdf:type http://purl.org/spar/fabio/BibliographicMetadata
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial rdf:type rdfs:Resource
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial rdf:type owl:Thing
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial rdf:type ripe:IntegrityAssessmentEvidenceIntegrity assessment evidence
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial rdf:type ripe:PublicationDetailsPublication details
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial rdf:type tido:Evidence
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial prov:wasGeneratedBy ripekg:evidence-aggregation/RIPEAE59AF25CB9D16527
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial prov:wasMemberOf ripekg:research-integrity-assessment/RIPEAE59AF25CB9D16527
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial ripe:concerns ripekg:work/10.1111%2Fpai.12978EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial tido:supports ripekg:integrity-assessment-hypothesis/RIPEAE59AF25CB9D16527-human-1-1
ripekg:publication-details/RIPEAE59AF25CB9D16527EXPRESSION OF CONCERN: The effects of melatonin administration on disease severity and sleep quality in children with atopic dermatitis: A randomized, double‐blinded, placebo‐controlled trial tido:supports ripekg:integrity-assessment-hypothesis/RIPEAE59AF25CB9D16527-inspectai-1-1